Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes
A re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan resulted in an increase in the notional allocation of Ordinary share ADRs. This transaction occurred on March 5, 2010, at a price of $38.26 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: March 5, 2010.
- Transaction Price: $38.26 per ADR.
- Plan Involved: US Retirement Savings Plan (notional investment in GSK Ordinary share ADRs).
- Individuals Notified: Dr M M Slaoui (63 units), Ms D Connelly (23 units), Mr W C Louv (97 units), and Dr D Pulman (82 units).
- Filing Date: March 9, 2010.